Efficacy of chemoradiotherapy with low-dose cisplatin and continuous infusion of 5-fluorouracil for unresectable squamous cell carcinoma of the esophagus

Diseases of the Esophagus

Volumn 22, Issue 6, 2009, Pages 482-489

  Takagawa, Ryo ^a   Kunisaki, Chikara ^b   Makino, Hirochika ^b   Kosaka, Takashi ^a   Ono, Hidetaka A ^a   Akiyama, Hirotoshi ^a   Shimada, Hiroshi ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

C reactive protein; Chemoradiotherapy; Esophageal cancer; Low dose chemotherapy; Unresectable esophageal cancer

Indexed keywords

C REACTIVE PROTEIN; CISPLATIN; FLUOROURACIL;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CERVICAL LYMPH NODE; CONTINUOUS INFUSION; DISTANT METASTASIS; DRUG EFFICACY; DRUG RESPONSE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGITIS; FEMALE; HUMAN; INOPERABLE CANCER; KIDNEY DYSFUNCTION; LEUKOPENIA; LOW DRUG DOSE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE FRACTIONATION; THORACIC AORTA; THROMBOCYTOPENIA; TRACHEOBRONCHIAL TREE; TUMOR LOCALIZATION;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; C-REACTIVE PROTEIN; CARCINOMA, SQUAMOUS CELL; CISPLATIN; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RADIATION-SENSITIZING AGENTS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 69249143726     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2008.00935.x     Document Type: Article

References (29)

1. Kamangar F, Dores G M, Anderson W F. Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-50.
2. Available from URL: http://ganjoho.ncc.go.jp/pro/statistics/en/ graph_db_index.html
3. NCCN Esophageal cancer: Clinical practice guideline in oncology - v.1.2008. http://www.nccn.org/professionals/physician_gls/ f_guidelines.asp
4. Scanlon K J, Newman Y L, Priest D G. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 1986; 83: 8923-5.
5. Byfield J E. Combined modality infusional chemotherapy with radiation. In: Lokich J J, (ed). Cancer Chemotherapy by Infusion, 2nd edn. Chicago, IL: Percepta Press, 1990; 521-51.
6. Herskovic A, Martz K, Al-Sarraf M et al. Combined chemotherapy and radiotherapy in patients with cancer of the esophagus. N Engl J Med 1992; 326: 1593-8.
7. Hsu C H, Yeh K H, Lui L T et al. Concurrent chemoradiotherapy for locally advanced esophageal cancer - a pilot study by using daily low-dose cisplatin and continuous infusion of 5-fluorouracil. Anticancer Res 1999; 19: 4463-7.
8. Sakai K, Sueyama H, Saito M et al. Long-term results of concurrent chemoradiotherapy using low-dose continuous infusion of 5-fluorouracil for stage II-III esophageal cancer. J Jpn Soc Ther Radiol Oncol 2001; 13: 97-101.
9. Nemoto K, Ogawa Y, Matsushita H et al. A pilot study of radiation therapy combined with daily low-dose cisplatin for esophageal cancer. Oncol Rep 2001; 8: 785-9.
10. Sobin L H, Wittekind C H. TNM: Classification of Malignant Tumours, 6th edn. New York: John Wiley and Sons, 2003.
11. Ando N, Ozawa S, Kitagawa Y, Shinozawa Y, Kitajima M. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg 2000; 232: 225-32.
12. Osugi H, Takemura M, Takada N, Hirohashi K, Kinoshita H, Higashino M. Prognostic factors after oesophagectomy and extended lymphadenectomy for squamous oesophageal cancer. Br J Surg 2002; 89: 909-13.
13. Ohtsu A, Boku N, Muro K et al. Definitive chemoradiotherapy for T4 and/ or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 1999; 17: 2915-21.
14. Kaneko K, Ito H, Mitamura K etal. Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the esophagus. Br J Cancer 2003; 88: 18-24.
15. Nishimura Y, Suzuki M, Nakamatsu K, Kanamori S, Shigeoka H. Prospective trial of concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil and cisplatin for T4 esophageal cancer with or without fistula. Int J Radiat Oncol Biol Phys 2002; 53: 134-9.
16. Ajani J A, Ilson D H, Daugherty K, Pazdur R, Lynch P M, Kelsen D P. Activity of Taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994; 86: 1086-91.
17. Muro K, Hamaguchi T, Ohtsu A et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 2004; 15: 955-9.
18. Mauer A M, Kraut E H, Krauss S A etal. Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. Ann Oncol 2005; 16 (8): 1320-5.
19. Ilson D H, Saltz L, Enzinger P et al. Phase II trial of weekly Irinotecan plus Cisplatin in ADVANCED Esophageal Cancer. Ann Oncol 2004; 15: 960-5.
20. Al-Sarraf M, Martz K, Herskovic A et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: An intergroup study. J Clin Oncol 1997; 15: 277-84.
21. Minsky B D, Pajak T F, Ginsberg R J et al. INT0123 (Radiation therapy oncology group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy. J Clin Oncol 2002; 20: 1167-74.
22. Sai H, Mitsumori M, Yamauchi C etal. Concurrent chemoradiotherapy for esophageal cancer: Comparison between intermittent standard-dose cisplatin with 5-fluorouracil and daily low-dose cisplatin with continuous infusion of 5-fluorouracil. Int J Clin Oncol 2004; 9: 149-53.
23. Sasamoto R, Sakai K, Inakoshi H etal. Long-turn results of chemoradiotherapy for locally advanced esophageal cancer, using daily low dose 5-fluorouracil and cis-diammine-dichloroplatinum (CDDP). Int J Clin Oncol 2007; 23: 25-30.
24. Ishikura S, Nihei K, Ohtsu A et al. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol 2003; 21: 2697-702.
25. Shimada H, Nabeya Y, Okazumi S et al. Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol 2003; 83: 248-52.
26. Crumley A B, McMillan D C, McKernan M, Going J J, Shearer C J, Stuart R C. An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer 2006; 94: 1568-71.
27. Kunisaki C, Imada T, Yamada R et al. Prognostic factors after chemoradiotherapy for patients with inoperable esophageal squamous cell carcinoma. Hepato-gastroenterol 2006; 53: 366-71.
28. Rades D, Tribius S, Yekebas E F et al. Epoetin alfa improves survival after chemoradiation for stage III esophageal cancer: Final results of a prospective observational study. Int J Radiat Oncol Biol Phys 2006; 65: 459-65.
29. Kader A S, Lim J T, Berthelet E, Petersen R, Ludgate D, Truong P T. Prognostic significance of blood transfusions in patients with esophageal cancer treated with combined chemoradiotherapy. Am J Clin Oncol 2007; 30: 492-7.